How I treat patients with adult onset Still's disease in clinical practice

Autoimmunity Reviews

Volumn 16, Issue 10, 2017, Pages 1016-1023

  Govoni, Marcello ^a   Bortoluzzi, Alessandra ^a   Rossi, Daniela ^b   Modena, Vittorio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b S GIOVANNI BOSCO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT ONSET STILL DISEASE; ARTHRALGIA; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE EXACERBATION; FEVER; HUMAN; LEUKOCYTOSIS; PATHOGENESIS; PATIENT CARE; PRACTICE GUIDELINE; RASH; REVIEW; SYNOVITIS; ADULT;

ADULT; HUMANS; STILL'S DISEASE, ADULT-ONSET;

EID: 85028940787     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2017.07.017     Document Type: Review

References (88)

1. Bywaters, E.G., Still's disease in the adult. Ann Rheum Dis 30:2 (Mar 1971), 121–133.
2. Still, G.F., On a form of chronic joint disease in children. Med Chir Trans 80 (1897), 47–60.
3. Jamilloux, Y., Gerfaud-Valentin, M., Martinon, F., Belot, A., Henry, T., Sève, P., Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. Immunol Res 61:1–2 (Feb 2015), 53–62, 10.1007/s12026-014-8561-9.
4. Magadur-Joly, G., Billaud, E., Barrier, J.H., Pennec, Y.L., Masson, C., Renou, P., et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 54:7 (Jul 1995), 587–590.
5. Narula, N., Narula, T., Abril, A., Seizing the clinical presentation in adult onset Still's disease. An extensive literature review. Autoimmun Rev 14 (2015), 472–477.
6. Evensen, K.J., Nossent, H.C., Epidemiology and outcome of adult-onset Still's disease in Northern Norway. Scand J Rheumatol 35:1 (Jan-Feb 2006), 48–51.
7. Balci, M.A., Pamuk, Ö.N., Pamuk, G.E., Uzundere, F.K., Donmez, S., Epidemiology and outcome of adult-onset Still's disease in Northwestern Thrace region in Turkey. Clin Exp Rheumatol 33:6 (Nov-Dec 2015), 818–823.
8. Asanuma, Y.F., Mimura, T., Tsuboi, H., Noma, H., Miyoshi, F., Yamamoto, K., et al. Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. Mod Rheumatol 25:3 (May 2015), 393–400, 10.3109/14397595.2014.974881.
9. Pay, S., Türkçapar, N., Kalyoncu, M., Simşek, I., Beyan, E., Ertenli, I., et al. A multicenter study of patients with adult-onset Still's disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol 25:5 (Sep 2006), 639–644.
10. Gerfaud-Valentin, M., Maucort-Boulch, D., Hot, A., Iwaz, J., Ninet, J., Durieu, I., et al. Adult-onset Still's disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 93:2 (Mar 2014), 91–99, 10.1097/MD.0000000000000021.
11. Kalyoncu, U., Solmaz, D., Emmungil, H., Yazici, A., Kasifoglu, T., Kimyon, G., et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: data from a large multicenter cohort. J Autoimmun 69 (May 2016), 59–63, 10.1016/j.jaut.2016.02.010.
12. Sfriso, P., Priori, R., Valesini, G., Rossi, S., Montecucco, C.M., D'Ascanio, A., et al. Adult-onset Still disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol 35:7 (Jul 2016), 1683–1689, 10.1007/s10067-016-3308-8.
13. Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J., Sève, P., Adult-onset Still disease. Autoimmun Rev 13:7 (Jul 2014), 708–722, 10.1016/j.autrev.2014.01.058.
14. Fautrel, B., Zing, E., Golmard, J.L., Le Moel, G., Bissery, A., Rioux, C., et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore) 81:3 (May 2002), 194–200.
15. Colina, M., Zucchini, W., Ciancio, G., Orzincolo, C., Trotta, F., Govoni, M., The evolution of adult-onset Still disease: an observational and comparative study in a cohort of 76 Italian patients. Semin Arthritis Rheum 41 (2011), 279–285, 10.1016/j.semarthrit.2010.12.006.
16. Castañeda, S., Blanco, R., González-Gay, M.A., Adult-onset Still's disease: advances in the treatment. Best Pract Res Clin Rheumatol 30:2 (Apr 2016), 222–238, 10.1016/j.berh.2016.08.003.
17. Fautrel, B., Le Moël, G., Saint-Marcoux, B., Taupin, P., Vignes, S., Rozenberg, S., et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol 28:2 (Feb 2001), 322–329.
18. Yamaguchi, M., Ohta, A., Tsunematsu, T., Kasukawa, R., Mizushima, Y., Kashiwagi, H., et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 19:3 (Mar 1992), 424–430.
19. Thibault Jacques Maria, A., Le Quellec, A., Jorgensen, C., Touitou, I., Rivière, S., Guilpain, P., Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13 (2014), 1149–1159.
20. Liozon, E., Ly, K.H., Vidal-Cathala, E., Fauchais, A.-L., Pseudomaladie de Still et néoplasie: une observation de mélanome et revuede la literature. Rev Med Interne 35 (2014), 60–64.
21. Kadavath, S., Efthimiou, P., Adult-onset Still's disease—pathogenesis, clinical manifestations, and new treatment options. Ann Med 47:1 (2015), 6–14, 10.3109/07853890.2014.971052.
22. Pouchot, J., Sampalis, J.S., Beaudet, F., Carette, S., Décary, F., Salusinsky-Sternbach, M., et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70 (1991), 118–136.
23. Ruscitti, P., Cipriani, P., Masedu, F., Iacono, D., Ciccia, F., Liakouli, V., et al. Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Med, 14(1), Dec 1 2016, 194.
24. Ravelli, A., Minoia, F., Davi, S., Horne, A., Bovis, F., Pistorio, A., et al. Development and initial validation of classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol, 2015, 10.1002/art.39332.
25. Gattorno, M., Piccini, A., Lasigliè, D., Tassi, S., Brisca, G., Carta, S., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 58 (2008), 1505–1515, 10.1002/art.23437.
26. Terkeltaub, R., Esdaile, J., Décary, F., Harth, M., Lister, J., Lapointe, N., HLA-Bw35 and prognosis in adult Still's disease. Arthritis Rheum 12 (1981), 1469–1472.
27. Wouters, J.M., Reekers, P., van de Putte, L.B., Adult-onset Still's disease. Disease course and HLA associations. Arthritis Rheum 29 (1986), 415–418.
28. Miller, M.L., Aaron, S., Jackson, J., Fraser, P., Cairns, L., Hoch, S., et al. HLA gene frequencies in children and adults with systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 28 (1985), 146–150.
29. Joung, C.I., Lee, H.S., Lee, S.W., Kim, C.G., Song, Y.H., Jun, J.B., et al. Association between HLA-DR B1 and clinical features of adult onset Still's disease in Korea. Clin Exp Rheumatol 21 (2003), 489–492.
30. Sugiura, T., Kawaguchi, Y., Harigai, M., Terajima-Ichida, H., Kitamura, Y., Furuya, T., et al. Association between adult-onset Still's disease and interleukin-18 gene polymorphisms. Genes Immun 3 (2002), 394–399.
31. Wang, F.-F., Huang, X.-F., Shen, N., Leng, L., Bucala, R., Chen, S.-L., et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease. Arthritis Res Ther, 15, 2013, R65.
32. Efthimiou, P., Kadavath, S., Mehta, B., Life-threatening complications of adult-onset Still's disease. Clin Rheumatol 33 (2014), 305–314.
33. Rosário, C., Zandman-Goddard, G., Meyron-Holtz, E.G., D'Cruz, D.P., Shoenfeld, Y., The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med, 11, 2013, 185 [http://www.biomedcentral.com/1741-7015/11/185].
34. Lee, S.J., Cho, Y.N., Kim, T.J., Park, S.C., Park, D.J., Jin, H.M., et al. Natural killer T cell deficiency in active adult-onset Still's disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. Arthritis Rheum 64:9 (Sep 2012), 2868–2877, 10.1002/art.34514.
35. Grom, A.A., Horne, A., De Benedetti, F., Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol 12:5 (May 2016), 259–268, 10.1038/nrrheum.2015.179.
36. Mavragani, C.P., Spyridakis, E.G., Koutsilieris, M., Adult-onset Still's disease: from pathophysiology to targeted therapies. Int J Inflamm, 2012, 10 pages, 10.1155/2012/879020 Article ID 879020.
37. Efthimiou, P., Paik, P.K., Bielory, L., Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 65 (2006), 564–572, 10.1136/ard.2005.042143.
38. Masson, C., Le Loët, X., Lioté, F., Renou, P., Dubost, J.J., Boissier, M.C., et al. Adult Still's disease. Part II. Management, outcome, and prognostic factors. Rev Rhum Engl Ed 62 (1995), 758–765.
39. Wouters, J.M., van de Putte, L.B., Adult-onset Still's disease; clinical and laboratory features, treatment and progress of 45 cases. Q J Med 61 (1986), 1055–1065.
40. Kong, X.-D., Xu, D., Zhang, W., Zhao, Y., Zeng, X., Zhang, F., Clinical features and prognosis in adult-onset Still's disease: a study of 104 cases. Clin Rheumatol 29 (2010), 1015–1019, 10.1007/s10067-010-1516-1.
41. Kim, H.-A., Sung, J.-M., Suh, C.-H., Therapeutic responses and prognosis in adult-onset Still's disease. Rheumatol Int 32 (2012), 1291–1298, 10.1007/s00296-011-1801-6.
42. Kraus, A., Alarcón-Segovia, D., Fever in adult onset Still's disease. Response to methotrexate. J Rheumatol 18 (1991), 918–920.
43. Aydintug, A.O., D'Cruz, D., Cervera, R., Khamashta, M.A., Hughes, G.R., Low dose methotrexate treatment in adult Still's disease. J Rheumatol 19 (1992), 431–435.
44. Fujii, T., Akizuki, M., Kameda, H., Matsumura, M., Hirakata, M., Yoshida, T., et al. Methotrexate treatment in patients with adult onset Still's disease—retrospective study of 13 Japanese cases. Ann Rheum Dis 56 (1997), 144–148.
45. Fautrel, B., Borget, C., Rozenberg, S., Meyer, O., Le Loët, X., Masson, C., et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 26 (1999), 373–378.
46. Franchini, S., Dagna, L., Salvo, F., Aiello, P., Baldissera, E., Sabbadini, M.G., Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum 62 (2010), 2530–2535, 10.1002/art.27532.
47. Segal, R., Mozes, E., Yaron, M., Tartakovsky, B., The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 32 (1989), 370–377.
48. Thomas, R., Carroll, G.J., Reduction of leukocyte and interleukin-1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 36 (1993), 1244–1252.
49. Barrera, P., Boerbooms, A.M., Demacker, P.N., van de Putte, L.B., Gallati, H., van der Meer, J.W., Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: effects of a single dose methotrexate. Br J Rheumatol 33 (1994), 1017–1024.
50. Pamuk, O.N., Pamuk, G.E., Usta, U., Cakir, N., Hemophagocytic syndrome in one patient with adult-onset Still's disease. Presentation with febrile neutropenia. Clin Rheumatol 26 (2007), 797–800, 10.1007/s10067-006-0238-x.
51. Kelly, A., Ramanan, A.V., A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol 4 (2008), 615–620, 10.1038/ncprheum0919.
52. Bruck, N., Suttorp, M., Kabus, M., Heubner, G., Gahr, M., Pessler, F., Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 17 (2011), 23–27, 10.1097/RHU.0b013e318205092d.
53. Record, J.L., Beukelman, T., Cron, R.Q., Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol 38 (2011), 180–181, 10.3899/jrheum.100726.
54. Stern, A., Riley, R., Buckley, L., Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. J Clin Rheumatol 7 (2001), 252–256.
55. Kaneko, K., Kaburaki, M., Muraoka, S., Tanaka, N., Yamamoto, T., Kusunoki, Y., et al. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis 13 (2010), e67–69, 10.1111/j.1756-185X.2010.01544.x.
56. Agarwal, S., Moodley, J., Ajani Goel, G., Theil, K.S., Mahmood, S.S., Lang, R.S., A rare trigger for macrophage activation syndrome. Rheumatol Int 31 (2011), 405–407, 10.1007/s00296-009-1204-0.
57. Lequerré, T., Quartier, P., Rosellini, D., Alaoui, F., De Bandt, M., Mejjad, O., et al. Interleukin-1 receptorantagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathicarthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67 (2008), 302–308, 10.1136/ard.2007.076034.
58. Nigrovic, P.A., Mannion, M., Prince, F.H.M., Zeft, A., Rabinovich, C.E., van Rossum, M.A.J., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 63 (2011), 545–555, 10.1002/art.30128.
59. Raffeiner, B., Botsios, C., Dinarello, C., Ometto, F., Punzi, L., Ramonda, R., Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine 78 (2011), 100–101, 10.1016/j.jbspin.2010.09.014.
60. Choi, A.D., Moles, V., Fuisz, A., Weissman, G., Cardiac magnetic resonance in myocarditis from adult onset Still's disease successfully treated with anakinra. Int J Cardiol 172 (2014), e225–227, 10.1016/j.ijcard.2013.12.151.
61. Luconi, N., Risse, J., Busato, T., Galland, J., Mandry, D., Voilliot, D., et al. Myocarditis in a young man with adult onset Still's disease successfully treated with Il-1 blocker. Int J Cardiol 189 (2015), 220–222, 10.1016/j.ijcard.2015.04.071.
62. Lanza, F., Dominici, M., Govoni, M., Moretti, S., Campioni, D., Corte, R.L., et al. Prolonged remission state of refractory adult onset Still's disease following CD34-selected autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 25 (2000), 1307–1310, 10.1038/sj.bmt.1702435.
63. Nirmala, N., Brachat, A., Feist, E., Blank, N., Specker, C., Witt, M., et al. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J, 13, 2015, 50, 10.1186/s12969-015-0047-3.
64. Fall, N., Barnes, M., Thornton, S., Luyrink, L., Olson, J., Ilowite, N.T., et al. Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum 56 (2007), 3793–3804, 10.1002/art.22981.
65. Ichida, H., Kawaguchi, Y., Sugiura, T., Takagi, K., Katsumata, Y., Gono, T., et al. Clinical manifestations of adult-onset Still's disease presenting with erosive arthritis: association with low levels of ferritin and interleukin-18. Arthritis Care Res 66 (2014), 642–646, 10.1002/acr.22194.
66. Shimizu, M., Nakagishi, Y., Yachie, A., Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 61 (2013), 345–348, 10.1016/j.cyto.2012.11.025.
67. Cavagna, L., Caporali, R., Epis, O., Bobbio-Pallavicini, F., Montecucco, C., Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 19 (2001), 329–332.
68. Kraetsch, H.G., Antoni, C., Kalden, J.R., Manger, B., Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 60:Suppl. 3 (2001), iii55–57.
69. Kokkinos, A., Iliopoulos, A., Greka, P., Efthymiou, A., Katsilambros, N., Sfikakis, P.P., Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol 23 (2004), 45–49, 10.1007/s10067-003-0775-5.
70. Fautrel, B., Sibilia, J., Mariette, X., Combe, B., Club Rhumatismes et Inflammation, Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 64 (2005), 262–266, 10.1136/ard.2004.024026.
71. Husni, M.E., Maier, A.L., Mease, P.J., Overman, S.S., Fraser, P., Gravallese, E.M., et al. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum 46 (2002), 1171–1176, 10.1002/art.10231.
72. Suematsu, R., Ohta, A., Matsuura, E., Takahashi, H., Fujii, T., Horiuchi, T., et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol 22 (2012), 712–719, 10.1007/s10165-011-0569-6.
73. Kontzias, A., Efthimiou, P., The use of canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum 42 (2012), 201–205, 10.1016/j.semarthrit.2012.03.004.
74. Lo Gullo, A., Caruso, A., Pipitone, N., Macchioni, P., Pazzola, G., Salvarani, C., Canakinumab in a case of adult onset Still's disease: efficacy only on systemic manifestations. Joint Bone Spine 81 (2014), 376–377, 10.1016/j.jbspin.2013.12.011.
75. Barsotti, S., Neri, R., Iacopetti, V., d'Ascanio, A., Talarico, R., Tripoli, A., et al. Successful treatment of refractory adult-onset still disease with canakinumab: a case report. J Clin Rheumatol, 20, 2014, 121, 10.1097/RHU.0000000000000082.
76. Petryna, O., Cush, J.J., Efthimiou, P., IL-1 trap rilonacept in refractory adult onset Still's disease. Ann Rheum Dis 71 (2012), 2056–2057, 10.1136/annrheumdis-2012-201409.
77. Quartuccio, L., Maset, M., De Vita, S., Efficacy of abatacept in a refractory case of adult-onset Still's disease. Clin Exp Rheumatol 28 (2010), 265–267.
78. Ostrowski, R.A., Tehrani, R., Kadanoff, R., Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol 17 (2011), 315–317, 10.1097/RHU.0b013e31822c53ad.
79. Ahmadi-Simab, K., Lamprecht, P., Jankowiak, C., Gross, W.L., Successful treatment of refractory adult onset Still's disease with rituximab. Ann Rheum Dis 65 (2006), 1117–1118, 10.1136/ard.2005.047621.
80. Bartoloni, E., Alunno, A., Luccioli, F., Santoboni, G., Gerli, R., Successful treatment of refractory adult-onset Still's disease with anti-CD20 monoclonal antibody. Clin Exp Rheumatol 27 (2009), 888–889.
81. Padilla-Ibarra, J., Sanchez-Ortiz, A., Sandoval-Castro, C., Ramos-Remus, C., Rituximab treatment for pulmonary arterial hypertension in adult-onset Still's disease. Clin Exp Rheumatol 31 (2013), 657–658.
82. Belfeki, N., SmitiKhanfir, M., Said, F., Hamzaoui, A., Ben Salem, T., Ben Ghorbel, I., et al. Successful treatment of refractory adult onset Still's disease with rituximab. Reumatismo 68 (2016), 159–162, 10.4081/reumatismo.2016.888.
83. Schäfer, E.J., Jung, W., Korsten, P., Combination immunosuppressive therapy including rituximab for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adult-onset Still's disease. Case Rep Rheumatol, 2016, 2016, 8605274, 10.1155/2016/8605274.
84. Diallo, A., Mekinian, A., Boukari, L., Mouas, H., Zamy, M., Nahon, P., et al. Severe hepatitis in a patient with adult-onset Still's disease treated with anakinra. Rev Med Interne 34 (2013), 168–170, 10.1016/j.revmed.2012.10.372.
85. Ahmed, O., Brahmania, M., Alsahafi, M., Alkhowaiter, S., Erb, S., Anakinra hepatotoxicity in a patient with adult-onset Still's disease. ACG Case Rep J 2 (2015), 173–174, 10.14309/crj.2015.45.
86. Banse, C., Vittecoq, O., Benhamou, Y., Gauthier-Prieur, M., Lequerré, T., Lévesque, H., Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine 80 (2013), 653–655, 10.1016/j.jbspin.2013.04.011.
87. De Bandt, M., Saint-Marcoux, B., Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 68 (2009), 153–154, 10.1136/ard.2008.088179.
88. Kobayashi, M., Takahashi, Y., Yamashita, H., Kaneko, H., Mimori, A., Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21 (2011), 92–96, 10.1007/s10165-010-0348-9.